Do different types of stress differentially alter behavioural and neurobiological outcomes associated with depression in rodent models
doi: 10.3389/fneur.2026.1788148 Received 15 January 2026 Revised 16 February 2026 Accepted 23 February 2026 Published 07 April 2026 Volume 17 - 2026 Edited by Paul Chazot, Durham University, United Kingdom Reviewed by Li Baojian, Shaanxi University of Chinese Medicine, China Ayokunmi Akinduko, Landmark University, Nigeria Updates Copyright 2026 Okomolo Moto, Diapa Tchiengang, Kameni Njapdounke, Mbom, Mbeboh Savo, Aren Arsaa, Nezoumne, Ndjock and Bum
Related Read: 14 Peptides Are About to Become Legal Again What This Means for Your Health What the science says about peptide stacking as a category 1) Combination trials are the exception, not the rule For many popular peptides, we have: mechanistic arguments small studies (sometimes in narrow contexts) preclinical work We rarely have: well-powered, long-term human trials on the combination hard outcomes (function, cardiometabolic endpoints, durability, safety) 2) Stacking amplifies the two biggest risks in this space Quality risk (variable purity, contamination, labeling issues) Physiology risk (more pathways affected, more unintended effects) 3) The GH/IGF-1 axis is where stacking gets most clinically delicate CJC-1295 has human data showing it raises GH/IGF-1
A randomized cohort study of the efficacy of PO magnesium in the treatment of acute concussions in adolescents
Gelatinase-sensitive nanoparticles loaded with photosensitizer and STAT3 inhibitor for cancer photothermal therapy and immunotherapy
